January 25, 2020
The Ayurvedic Herb Brahmi (Bacopa monnieri) For Treating Alzheimer's Disease

The Ayurvedic Herb Brahmi (Bacopa monnieri) For Treating Alzheimer’s Disease

Brahmi (Bacopa monnieri) is a popular nootropic Ayurvedic medicinal herb with a long traditional history of being recommended for treating neurological disorders and as a memory enhancer.

Bacopa monnieri also commonly known as “Brahmi”, water hyssop, thyme-leafed gratiola, herb of grace, and Indian pennywort is a perennial, creeping herb native to the wetlands of southern and Eastern India, Australia, Europe, Africa, Asia, and North and South America.

Brahmi is considered to have “nootropic” properties and is traditionally recommended to improve memory and treat neurological disorders.

Nootropics are drugs, supplements, and other substances that may improve cognitive function, memory, creativity, or motivation, in healthy individuals.

Emerging scientific evidence is now beginning to confirm many of the potential neuroprotective and cognitive enhancing benefits of Brahmi.

Numerous animal and in vitro studies have been conducted, with many evidencing potential medicinal properties.

Several randomized, double-blind, placebo-controlled trials have substantiated BM’s nootropic utility in humans. There is also evidence for potential attenuation of dementia, Parkinson’s disease, and epilepsy. [4]

Brahmi’s Active Constituents & Mechanisms

Bacosides from Bacopa monnieri (B monnieri) are examples of a valuable therapeutic agent for AD due to their anti-inflammatory, antioxidant, and Aβ aggregation inhibitor properties. [3]

Bacoside A, Bacoside B, Bacosaponins, Betulinic acid, etc; are the bioactive component of Brahmi belonging to various chemical families. Each chemical component known have its significant role in neuroprotection.

The neuroprotective properties of Brahmi and its bioactive components including reduction of ROS, neuroinflammation, aggregation inhibition of Amyloid-β and improvement of cognitive and learning behaviour. [1]

Current evidence suggests BM acts via the following mechanisms—anti-oxidant neuroprotection (via redox and enzyme induction), acetylcholinesterase inhibition and/or choline acetyltransferase activation, β-amyloid reduction, increased cerebral blood flow, and neurotransmitter modulation (acetylcholine [ACh], 5-hydroxytryptamine [5-HT], dopamine [DA]). [4]

Let’s take a look at what the current scientific evidence is concluding on the herb Brahmi and its potential neurocognitive health benefits.

Study Conclusion:

“The overall studies have concluded that Brahmi can be used as a lead formulation for treatment of Alzheimer’s disease and other neurological disorders.” [1]

“This review reveals the effective use of B monnieri in cognition and neuroprotection and its phytoconstituents that can be used in novel drug discovery.” [3]

“Pase et al. conducted a systematic review, finding some evidence that “Bacopa could potentially be clinically prescribed as a memory enhancer” even in non-demented subjects.” [4]

“The results of our clinical trial show that Bacopa monnieri standardized extract (Bacognize® 300 mg twice a day orally) for 6 months results in improvement in some aspects of cognitive functions in geriatric patients suffering from Alzheimer’s disease.” [5]

References

[1] Brahmi (Bacopa monnieri): An ayurvedic herb against the Alzheimer’s disease.

https://www.ncbi.nlm.nih.gov/pubmed/31622587

[2] Neurocognitive Effect of Nootropic Drug Brahmi (Bacopa monnieri) in Alzheimer’s Disease

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448442/

[3] Bacopa monnieri, a Neuroprotective Lead in Alzheimer Disease: A Review on Its Properties, Mechanisms of Action, and Preclinical and Clinical Studies

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6669844/

[4] Neuropharmacological Review of the Nootropic Herb Bacopa monnieri

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3746283/

[5] Effect of Bacopa monnieri on Cognitive functions in Alzheimer’s disease patients

http://internalmedicine.imedpub.com/effect-of-bacopa-monnieri-on-cognitive-functions-inalzheimers-disease-patients.php?aid=6136

The information in this article has not been evaluated by the FDA and should not be used to diagnose, cure or treat any disease, implied or otherwise.

Leave a Reply

Your email address will not be published. Required fields are marked *